Dynavax Technologies Co. (NASDAQ:DVAX) Position Boosted by Bank of New York Mellon Corp

Bank of New York Mellon Corp grew its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 4.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 931,328 shares of the biopharmaceutical company’s stock after purchasing an additional 39,513 shares during the period. Bank of New York Mellon Corp owned about 0.71% of Dynavax Technologies worth $11,893,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. US Bancorp DE lifted its position in Dynavax Technologies by 291.4% in the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 2,034 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Dynavax Technologies by 55.1% in the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock worth $52,000 after acquiring an additional 1,457 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in shares of Dynavax Technologies during the fourth quarter worth $71,000. Nisa Investment Advisors LLC boosted its position in Dynavax Technologies by 19.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 1,076 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new position in Dynavax Technologies in the third quarter valued at about $89,000. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Stock Performance

DVAX opened at $13.69 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The company has a market cap of $1.70 billion, a PE ratio of 76.06 and a beta of 1.23. The stock has a 50-day moving average of $13.09 and a 200-day moving average of $12.28. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, hitting the consensus estimate of $0.05. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The firm had revenue of $72.03 million during the quarter, compared to analyst estimates of $72.70 million. As a group, equities research analysts forecast that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on DVAX shares. StockNews.com raised Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Monday, February 24th. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st. HC Wainwright reissued a “buy” rating and issued a $31.00 target price on shares of Dynavax Technologies in a research report on Friday, February 21st. Finally, The Goldman Sachs Group lowered shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and dropped their price target for the stock from $15.00 to $12.00 in a research note on Tuesday, February 11th.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.